via University of Waterloo
Researchers at the University of Waterloo are developing a DNA-based vaccine that can be delivered through a nasal spray.
The vaccine will work by using bacteriophage, a process that will allow the vaccine to replicate within bacteria already in the body and is being designed to target tissues in the nasal cavity and lower respiratory tract.
“When complete, our DNA-based vaccine will be administered non-invasively as a nasal spray that delivers nanomedicine engineered to immunize and decrease COVID-19 infections,” explains Roderick Slavcev, a professor in the School of Pharmacy who specializes in designing vaccines, pharmaceuticals and gene-therapy treatments. “This research combines the expertise of many and leverages existing technology developed by my team, which we’re reconfiguring for a COVID-19 application.”
When completed, the researchers aim to have the DNA-based vaccine enter cells in targeted tissues and cause them to produce a virus-like particle (VLP) that will stimulate an immune response in people.
The VLP will look similar to the structure of SARS-CoV-2 (the virus which causes COVID-19), but is harmless. This similarity will activate the body’s natural immune response to protect against viral infections comparable to the VLP, including SARS-CoV-2. It will also bind to receptors that SARS-CoV-2 would bind to, limiting the possible sites for transmission. By causing these changes in the body, the vaccine will build immunity against COVID-19 and decrease the severity of infections in progress – serving as both a therapeutic and a vaccine.
Every detail of the vaccine, from ensuring the bacteriophage target specific cells in the respiratory tract to creating a minimal VLP to impersonate SARS-CoV-2, is specifically engineered by the researchers and requires testing.
To achieve the design of such a complex project, Slavcev is teaming up with Emmanuel Ho, another professor at the School of Pharmacy, and Marc Aucoin, professor of chemical engineering. Ho’s team is designing the nanomedication that will be delivered by the nasal spray, which is currently being tested. Aucoin’s lab is constructing and purifying the VLP and boosting immunity following the initial administration of the therapeutic vaccine.
“It is the collaborative effort of our talented teams that makes this multidisciplinary project so feasible and necessarily efficient as a potential universal vaccine solution against SARS-CoV infections,” says Slavcev. “To practice science with such urgency alongside such talented colleagues and their students is not only immensely educational, it is extremely rewarding.”
Slavcev’s team has completed design of the bacteriophage delivery system and is currently modifying this system to apply to COVID-19. Additional design of components and further testing will take place later this year. Components of the research are supported by a grant from the Natural Sciences and Engineering Research Council of Canada.
Note: This research has not yet been peer-reviewed and is being released as part of UWaterloo’s commitment to help inform Canada’s COVID-19 response.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
DNA-based COVID-19 vaccine
- OP-ED: A close look at each vaccine developed so faron February 27, 2021 at 10:09 pm
The development of a safe and effective vaccine against Covid-19 was the most pressing challenge of our time, as it was “the” exit strategy from the pandemic. In the past few months, a couple of ...
- Your COVID-19 vaccine safety questions, answered by expertson February 27, 2021 at 10:44 am
Since August, we've been collecting your queries and concerns about the COVID vaccines. Here have the answers.
- 'All ready to go': Ottawa manufacturing centre producing three COVID vaccines for human trialson February 26, 2021 at 3:34 pm
The Ottawa Hospital’s Biotherapeutics Manufacturing Centre is producing three experimental COVID-19 vaccines for human trials. The first of the three, a DNA-based vaccine called Covigenix VAX-001, is ...
- The Ottawa Hospital partners with company to manufacture COVID-19 vaccineon February 26, 2021 at 1:17 am
The Ottawa Hospital has formed a partnership to complete the final stage of manufacturing the Entos Pharmaceuticals COVID-19 vaccine, filling the vials before they are sent off to inoculate patients.
- Ottawa Hospital to manufacture COVID-19 vaccineon February 25, 2021 at 12:40 pm
The Ottawa Hospital announced its Biotherapeutics Manufacturing Centre (BMC) will fill a critical gap in Canada's vaccine manufacturing capacity.
Go deeper with Google Headlines on:
DNA-based COVID-19 vaccine
Go deeper with Bing News on:
- Covid-19 Vaccines Yield Breakthroughs in Long-Term Fight Against Infections Diseaseon February 28, 2021 at 10:34 am
Researchers in gene-based technology produced a class of vaccines they believe can protect against all manner of infectious disease in the years to come.
- More than 20 million in Britain get first COVID-19 vaccine doseon February 28, 2021 at 9:45 am
More than 20 million people across the United Kingdom have now received their first COVID-19 vaccine shot, data showed on Sunday as the country made more progress with Europe's fastest vaccination ...
- FDA moves to authorise Johnson & Johnson’s Covid-19 vaccineon February 28, 2021 at 9:10 am
The US drugs regulator has decided to grant emergency approval in the coming days to Johnson & Johnson’s coronavirus vaccine, making it the country’s third vaccine and the first to require only a ...
- Philippines receives COVID-19 vaccine after delayson February 28, 2021 at 8:37 am
The Philippines received its first batch of COVID-19 vaccine Sunday, among the last in Southeast Asia to secure the critical doses despite having the ...
- Facebook groups and 14-hour car rides. Some Michigan residents are 'desperate' for the COVID-19 vaccine.on February 28, 2021 at 8:30 am
Getting an appointment for a COVID-19 vaccine has been elusive for many Michiganders, leading some to go to drastic lengths to get a shot in the arm.